Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Bilateral Nucleus Accumbens Focused Ultrasound Neuromodulation for Stimulant Use Disorder

NCT: NCT06474026 · RECRUITING

NCT IDNCT06474026
StatusRECRUITING
Start Date2024-07-01
Completion2027-07-31
SponsorKorea University Anam Hospital (OTHER)
First posted
Last updated

Brief Summary

The purpose of this clinical trial is to evaluate the initial safety and efficacy of the ExAblate Model 4000 Type 2.1 surgical device for nucleus accumbens (NAc) neuromodulation in patients with psychostimulant use disorder (PUD).

Frequently Asked Questions

What is Bilateral Nucleus Accumbens Focused Ultrasound Neuromodulation for Stimulant Use Disorder?

Bilateral Nucleus Accumbens Focused Ultrasound Neuromodulation for Stimulant Use Disorder is a clinical trial registered under NCT06474026. Current status: RECRUITING.

What is the status of NCT06474026?

The current status of NCT06474026 (Bilateral Nucleus Accumbens Focused Ultrasound Neuromodulation for Stimulant Use Disorder) is: RECRUITING.

When did Bilateral Nucleus Accumbens Focused Ultrasound Neuromodulation for Stimulant Use Disorder start?

Bilateral Nucleus Accumbens Focused Ultrasound Neuromodulation for Stimulant Use Disorder started on 2024-07-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑